| FUNDAMENTALS |
| MarketCap: |
2.54 mill
|
| EPS: |
0
|
| P/E: |
0
|
| Earnings Date: |
May 16, 2024 |
| SharesOutstanding: |
4 230.12 mill
|
| Avg Daily Volume: |
22.35 mill
|
| RATING
2024-05-03 |
|
B-
|
|
Sell
|
| RATINGS |
| Rating CashFlow: |
Strong Sell
|
|
| Return On Equity: |
Strong Sell
|
|
| Return On Asset: |
Strong Sell
|
|
| DE: |
Strong Buy
|
|
| P/E: |
Sell
|
|
| Price To Book: |
Buy
|
|
| QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
| Revenue | | | | | | |
| Gr.Profit | | | | | | |
| Ebit | | | | | | |
| Asset | | | | | | |
| Debt | | | | | | |
| PE RATIO: COMPANY / SECTOR |
|
0.00x
|
|
Company: PE 0 | sector: PE -11.58
|
| PE RATIO: COMPANY / INDUSTRY |
|
N/A
|
|
Company: PE 0 | industry: PE -107.25
|
| DISCOUNTED CASH FLOW VALUE |
|
N/A
|
|
N/A
|
| Expected Trading Range (DAY) |
$ 0.0006 - 0.0006
( +/- 0.00%)
|
|
ATR Model: 14 days
|
Insider Trading
| Date |
Person |
Action |
Amount |
type |
| 2024-04-18 | Dixon Timothy G | Buy | 42 857 142 | Common Stock |
| 2024-04-18 | Ichim Thomas | Buy | 15 000 000 | Common Stock |
| 2024-02-26 | Ichim Thomas | Buy | 10 000 000 | Common Stock |
| 2024-02-26 | Dixon Timothy G | Buy | 10 000 000 | Common Stock |
| 2023-10-16 | Ichim Thomas | Buy | 20 000 000 | Common Stock |
| INSIDER POWER |
|
96.92
|
| Last
93 transactions |
| Buy:
846 892 711 | Sell:
287 531 261 |
Forecast:
15:13 - $0.0010
Live Trading Signals (every 1 min)
Forecast
1: 13:43 - $0.0010
Forecast 2: 14:33 - $0.0010
Forecast 3: 15:13 - $0.0010
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
| Indicator Signals |
| RSI 21 |
|
| SMA |
|
| Trend |
|
| Trend 2 |
|
| Trend 3 |
|
| MACD |
|
| Volume Signals |
| Price |
$0.0006 (9.09% )
|
| Volume |
57.89 mill
|
| Avg. Vol. |
22.35 mill
|
| % of Avg. Vol |
258.96 %
|
| Signal 1: |
|
| Signal 2: |
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TSOI
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products include QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPlus, a blend of NanoStilbene and Nano Cannabidiol; Nano Cannabidiol, a nanoparticle formulation of cannabidiol; NanoPSA, a blend of NanoStilbene and broccoli sprout extract; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. It is also developing therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology. Therapeutic Solutions International, Inc. was founded in 2007 and is based in Elk City, Idaho.
The Technical Analyst
